Skye Bioscience, Inc. (SKYE) — Financial statements
Income statement, balance sheet, and cash flow for Skye Bioscience, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.72 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.72 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 42↑126.5% | 19↑221.4% | 6↓3.2% | 6↑105.1% | 3 | |
| General & Administrative Expenses | 16↓10.9% | 18↑125.7% | 8↑28.8% | 6↑24.0% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↓10.9% | 18↑125.7% | 8↑28.8% | 6↑24.0% | 5 | |
| Other Expenses | -0.72↑88.4% | -6↓129.6% | 21↑239.4% | 6 | 0.00 | |
| Operating Expenses | 57↑90.2% | 30↓13.1% | 35↑89.7% | 18↑133.3% | 8 | |
| Total Costs & Expenses | 58↑92.6% | 30↓13.1% | 35↑89.7% | 18↑133.3% | 8 | |
| Operating Results | ||||||
| Operating Income | -58↓92.6% | -30↑13.1% | -35↓89.7% | -18↓133.3% | -8 | |
| Depreciation & Amortization | 0.72↑142.2% | 0.30↑140.4% | 0.12↑8.0% | 0.11↑236.9% | 0.03 | |
| EBITDA | -57↓127.1% | -25↑30.9% | -37↓95.9% | -19↓142.2% | -8 | |
| EBIT | -58↓127.3% | -26↑30.4% | -37↓95.3% | -19↓142.6% | -8 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓17.9% | 2↑384.7% | -0.81↓25.1% | -0.64↑16.0% | -0.77 | |
| Interest Income | 2↓42.3% | 3↑3164.4% | 0.10↑425.9% | 0.02↑633600.0% | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.97↑6.8% | 0.91↑36.5% | 0.66↓13.5% | 0.77 | |
| Non-Operating Income | 0.00↑100.0% | -5↓329.2% | 2↑302.3% | 0.50↑624.8% | -0.10 | |
| Other Income / Expenses | 2↓38.3% | 4↑225.1% | -3↓149.8% | -1↓73.0% | -0.67 | |
| Income Before Tax | -56↓110.6% | -27↑29.4% | -38↓93.3% | -19↓128.6% | -9 | |
| Income Tax Expense | 0.01↓46.4% | 0.01↑179.8% | 0.00↓46.6% | 0.01↑221.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -56↓110.5% | -27↑29.4% | -38↓93.2% | -19↓128.6% | -9 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -56↓110.5% | -27↑29.4% | -38↓93.2% | -19↓128.6% | -9 | |
| Bottom-Line Net Income | -56↓110.5% | -27↑29.4% | -38↓93.2% | -19↓128.6% | -9 | |
| EPS (Basic) | -1.41↓93.2% | -0.73↑86.4% | -5.37↑38.8% | -8.77↓75.4% | -5.00 | |
| EPS (Diluted) | -1.41↓93.2% | -0.73↑86.4% | -5.37↑38.8% | -8.77↓75.4% | -5.00 | |
| Weighted Average Shares | 40↑8.7% | 36↑420.8% | 7↑215.4% | 2↑36.6% | 2 | |
| Weighted Average Diluted Shares | 40↑8.7% | 36↑420.8% | 7↑215.4% | 2↑36.6% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.